Predictions of time to HIV viral rebound following ART suspension that incorporate personal biomarkers

Antiretroviral therapy (ART) effectively controls HIV infection, suppressing HIV viral loads. Suspension of therapy is followed by rebound of viral loads to high, pre-therapy levels. However, there is significant heterogeneity in speed of rebound, with some rebounds occurring within days, weeks, or sometimes years. We present a stochastic mathematical model to gain insight into these post-treatment dynamics, specifically characterizing the dynamics of short term viral rebounds (≤ 60 days). Li et al. (2016) report that the size of the expressed HIV reservoir, i.e., cell-associated HIV RNA levels, and drug regimen correlate with the time between ART suspension and viral rebound to detectable levels. We incorporate this information and viral rebound times to parametrize our model. We then investigate insights offered by our model into the underlying dynamics of the latent reservoir. In particular, we refine previous estimates of viral recrudescence after ART interruption by accounting for heterogeneity in infection rebound dynamics, and determine a recrudescence rate of once every 2-4 days. Our parametrized model can be used to aid in design of clinical trials to study viral dynamics following analytic treatment interruption. We show how to derive informative personalized testing frequencies from our model and offer a proof-of-concept example. Our results represent first steps towards a model that can make predictions on a person living with HIV (PLWH)’s rebound time distribution based on biomarkers, and help identify PLWH with long viral rebound delays.

[1]  A. Perelson,et al.  Modeling the Effects of Vorinostat In Vivo Reveals both Transient and Delayed HIV Transcriptional Activation and Minimal Killing of Latently Infected Cells , 2015, PLoS pathogens.

[2]  C. Fletcher,et al.  A Antiretroviral Drug Penetration into Lymphoid Tissue , 2015 .

[3]  K. Tashima,et al.  Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  S. Lewin,et al.  Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5–8 Days , 2016, PLoS pathogens.

[5]  A. Perelson,et al.  Probabilistic control of HIV latency and transactivation by the Tat gene circuit , 2018, Proceedings of the National Academy of Sciences.

[6]  D. Douek HIV Infection: Advances Toward a Cure. , 2018, Topics in antiviral medicine.

[7]  R. Lempicki,et al.  HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Sarah B. Laskey,et al.  Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure , 2013, Cell.

[9]  M. Lederman,et al.  HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers , 2018, The Journal of clinical investigation.

[10]  Alan S. Perelson,et al.  Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaques , 2007, Proceedings of the National Academy of Sciences.

[11]  D. Richman,et al.  Absence of detectable HIV-1 viremia after treatment cessation in an infant. , 2013, The New England journal of medicine.

[12]  S. Hughes,et al.  Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo , 2016, Proceedings of the National Academy of Sciences.

[13]  Martin A. Nowak,et al.  Antiretroviral dynamics determines HIV evolution and predicts therapy outcome , 2012, Nature Medicine.

[14]  Nancie M Archin,et al.  Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies. , 2015, The Journal of infectious diseases.

[15]  Igor M. Rouzine,et al.  A Hardwired HIV Latency Program , 2015, Cell.

[16]  R. Siliciano,et al.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells , 2003, Nature Medicine.

[17]  Daniel I. S. Rosenbloom,et al.  Corrections: Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1 (Proc Natl Acad Sci USA (2014) 111, (13475-13480) doi: 10.1073/pnas.1406663111) , 2014 .

[18]  Eric J. Arts,et al.  Changes in Human Immunodeficiency Virus Type 1 Fitness and Genetic Diversity during Disease Progression , 2005, Journal of Virology.

[19]  Daniel Coombs,et al.  Stochastic Analysis of Pre- and Postexposure Prophylaxis against HIV Infection , 2013, SIAM J. Appl. Math..

[20]  B. Walker,et al.  The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies , 2018, The Journal of infectious diseases.

[21]  J. Lawrence,et al.  A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024). , 2006, The Journal of infectious diseases.

[22]  Feng Fu,et al.  Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1 , 2014, Proceedings of the National Academy of Sciences.

[23]  Alan S. Perelson,et al.  Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.

[24]  Brigitte Autran,et al.  Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study , 2013, PLoS pathogens.

[25]  M. Carrington,et al.  HIV-1 DNA predicts disease progression and post-treatment virological control , 2014, eLife.

[26]  David R. Anderson,et al.  Model selection and multimodel inference : a practical information-theoretic approach , 2003 .

[27]  B. Berkhout,et al.  What do we measure when we measure cell-associated HIV RNA , 2018, Retrovirology.

[28]  F. Mentré,et al.  Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action , 2010, Clinical pharmacokinetics.

[29]  Alan S. Perelson,et al.  Early HIV Infection Predictions: Role of Viral Replication Errors , 2018, SIAM J. Appl. Math..

[30]  J. Blankson Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses? , 2010, Antiviral research.

[31]  D. Richman,et al.  Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: Intrinsic stability predicts lifelong persistence , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Alan S. Perelson,et al.  A Novel Antiviral Intervention Results in More Accurate Assessment of Human Immunodeficiency Virus Type 1 Replication Dynamics and T-Cell Decay In Vivo , 2003, Journal of Virology.

[33]  Jessica M Conway,et al.  Post-treatment control of HIV infection , 2015, Proceedings of the National Academy of Sciences.

[34]  J. Lifson,et al.  Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy , 2017, PLoS pathogens.

[35]  G. Gao,et al.  PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors. , 2007, Blood.

[36]  K. P. Murphy,et al.  Janeway's immunobiology , 2007 .

[37]  M. Lederman,et al.  The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption , 2015, AIDS.

[38]  Daniel I. S. Rosenbloom,et al.  Insufficient Evidence for Rare Activation of Latent HIV in the Absence of Reservoir-Reducing Interventions , 2016, PLoS pathogens.

[39]  Alan S. Perelson,et al.  Stochastic Theory of Early Viral Infection: Continuous versus Burst Production of Virions , 2011, PLoS Comput. Biol..

[40]  Sebastian Bonhoeffer,et al.  Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis , 1999, The Lancet.

[41]  R. D. de Boer,et al.  Do Most Lymphocytes in Humans Really Reside in the Gut? , 2022 .

[42]  Alan S. Perelson,et al.  Residual Viremia in Treated HIV+ Individuals , 2016, PLoS Comput. Biol..

[43]  C. Rouzioux,et al.  Hiv-1 Control after Transient Antiretroviral Treatment Initiated in Primary Infection: Role of Patient Characteristics and Effect of Therapy , 2012, Antiviral therapy.

[44]  Hartmut Derendorf,et al.  Modeling of Pharmacokinetic/Pharmacodynamic (PK/PD) Relationships: Concepts and Perspectives , 1999, Pharmaceutical Research.

[45]  A. Haase,et al.  Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption , 2015, Proceedings of the National Academy of Sciences.

[46]  J. Mellors,et al.  The need for treatment interruption studies and biomarker identification in the search for an HIV cure. , 2015, AIDS.

[47]  Geneviève Boucher,et al.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation , 2009, Nature Medicine.

[48]  R. Siliciano,et al.  Recent developments in the search for a cure for HIV-1 infection: targeting the latent reservoir for HIV-1. , 2014, The Journal of allergy and clinical immunology.

[49]  V. Johnson,et al.  Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. , 2006, The Journal of infectious diseases.

[50]  C. Rouzioux,et al.  HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[51]  R. Siliciano,et al.  Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations , 2015, Nature.

[52]  J. Shuter Forgiveness of non-adherence to HIV-1 antiretroviral therapy. , 2008, The Journal of antimicrobial chemotherapy.

[53]  Emily B Hanhauser,et al.  Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV , 2016, PLoS pathogens.

[54]  Ruy M Ribeiro,et al.  Modeling the within-host dynamics of HIV infection , 2013, BMC Biology.

[55]  Alan S Perelson,et al.  Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues , 2014, Proceedings of the National Academy of Sciences.

[56]  Alan S. Perelson,et al.  Mathematical Analysis of HIV-1 Dynamics in Vivo , 1999, SIAM Rev..

[57]  Matthew C Strain,et al.  Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. , 2005, The Journal of infectious diseases.

[58]  A S Perelson,et al.  Modeling plasma virus concentration during primary HIV infection. , 2000, Journal of theoretical biology.

[59]  M. Carrington,et al.  Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study , 2014, AIDS.

[60]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[61]  E. Rosenberg,et al.  Safety and Immunogenicity of Therapeutic DNA Vaccination in Individuals Treated with Antiretroviral Therapy during Acute/Early HIV-1 Infection , 2010, PLoS ONE.

[62]  R. Schooley,et al.  AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. , 2010, The Journal of infectious diseases.

[63]  Sebastian Bonhoeffer,et al.  Decelerating Decay of Latently Infected Cells during Prolonged Therapy for Human Immunodeficiency Virus Type 1 Infection , 2002, Journal of Virology.

[64]  Daniel Coombs,et al.  A Stochastic Model of Latently Infected Cell Reactivation and Viral Blip Generation in Treated HIV Patients , 2011, PLoS Comput. Biol..

[65]  M. Proschan,et al.  A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection , 2017, Science Translational Medicine.

[66]  Lin Shen,et al.  Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs , 2008, Nature Medicine.

[67]  Libin Rong,et al.  Modeling HIV persistence, the latent reservoir, and viral blips. , 2009, Journal of theoretical biology.

[68]  M. Hirsch,et al.  Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment , 2009, AIDS.

[69]  P. Goulder,et al.  Post-treatment control or treated controllers? Viral remission in treated and untreated primary HIV infection , 2017, AIDS.

[70]  M. Lederman,et al.  Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy , 2015, Journal of Virology.

[71]  A. Perelson Modelling viral and immune system dynamics , 2002, Nature Reviews Immunology.

[72]  H. T. Banksa,et al.  Estimation and Prediction With HIV-Treatment Interruption Data , 2007 .

[73]  D. Freedman,et al.  Multistage models for carcinogenesis. , 1989, Environmental health perspectives.

[74]  C. Boucher,et al.  Unite forces to validate biomarkers in the quest for lasting HIV remission. , 2016, AIDS.

[75]  D. Havlir,et al.  Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. , 2007, The Journal of infectious diseases.

[76]  Taina T. Immonen,et al.  Principles Governing Establishment versus Collapse of HIV-1 Cellular Spread. , 2019, Cell host & microbe.

[77]  S. Hughes,et al.  Specific HIV integration sites are linked to clonal expansion and persistence of infected cells , 2014, Science.

[78]  M. L. Simpson,et al.  Transcriptional bursting from the HIV-1 promoter is a significant source of stochastic noise in HIV-1 gene expression. , 2010, Biophysical journal.

[79]  R. Phillips,et al.  Immunological biomarkers predict HIV-1 viral rebound after treatment interruption , 2015, Nature Communications.

[80]  Simon Wain-Hobson Virus Dynamics: Mathematical Principles of Immunology and Virology , 2001, Nature Medicine.

[81]  R. Siliciano,et al.  HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study , 2017, PLoS medicine.

[82]  Anthony D. Kelleher,et al.  HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission , 2015, PLoS pathogens.